You are here:

Home
NICE Guidance
Conditions and diseases
Blood and immune system conditions
Blood and bone marrow cancers

Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia

Technology appraisal guidance
Reference number: TA193
Published: 28 July 2010

Guidance
Tools and resources
Information for the public
History

Appendix B: GE decision paper - March 2014

Appendix B: GE decision paper - March 2014

Appendix B: GE decision paper - March 2014
08 April 2014
(110.09 Kb 32 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 08 April 2014